Business
Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes Care
By Johnny Rice Benzinga DETROIT, MICHIGAN - March 19, 2025 (NEWMEDIAWIRE) - Paul Goode, President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on
About this update from Glucotrack, Inc.
By Johnny Rice Benzinga DETROIT, MICHIGAN - March 19, 2025 ( NEWMEDIAWIRE ) - Paul Goode , President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on Benzinga's All-Access. GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring (CBGM) technology provides discreet, accurate, real-time glucose readings. The company's vision is to create a future where diabetes management is automatic and inconspicuous, empowering people to live boldly and unapologetically. Learn more here: https://www.youtube.com/watch?v=xjn-_aLseTc&feature=youtu.be Featured photo by Towfiqu barbhuiya on Unsplash . This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. This content was originally published on Benzinga . Read further disclosures here.